Caris Life Sciences (CAI) P/E ratio
There is no P/E ratio history on record here for Caris Life Sciences (CAI). Caris Life Sciences (CAI) trades at 12.0× its earnings per share over the last twelve months. Figures as of 18 Nov 2026, 09:28 UTC, from Yahoo Finance.
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/E ratio needs at least 3 fiscal years; none is on record here for Caris Life Sciences. Nothing is estimated to fill the gap. What is on record is in the table below.
Caris Life Sciences P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| Today | 12.0× | — | $19.94 | — | |
| 2025 | — | — | $26.98 | -$3.22 | |
| 2024 | — | — | — | -$1.36 | |
| 2023 | — | — | — | -$1.82 | |
| 2022 | — | — | — | -$1.57 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| Amneal Pharmaceuticals AMRX | 52.8× |
| Caris Life Sciences CAI | 12.0× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
Caris Life Sciences, figure by figure
- Caris Life Sciences market cap
- Caris Life Sciences revenue
- Caris Life Sciences earnings
- Caris Life Sciences earnings per share (EPS)
- Caris Life Sciences P/S ratio
- Caris Life Sciences P/B ratio
- Caris Life Sciences free cash flow
- Caris Life Sciences operating margin
- Caris Life Sciences dividend
- Caris Life Sciences shares outstanding
- Caris Life Sciences total debt
- Caris Life Sciences cash on hand
- Caris Life Sciences total assets
- Caris Life Sciences return on equity (ROE)
- Caris Life Sciences return on invested capital (ROIC)
Caris Life Sciences (CAI) overview: price, valuation and scorecardAll health care companies by market value
Caris Life Sciences P/E ratio: questions and answers
What is Caris Life Sciences's P/E ratio?
Caris Life Sciences (CAI) trades at 12.0× its earnings per share over the last twelve months.
How is Caris Life Sciences's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Caris Life Sciences (CAI) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CAI/pe-ratio
Underlying data: Yahoo Finance.